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CLINICAL AND EPIDEMIOLOGIC RESEARCH

The Spectrum of Eye Disease in Hospitalized Adults
Living with HIV, 1995–2010
Christopher Miller, MD,1 William R. Short, MD, MPH,1,6 Lorena Perez-Povis, MD,1,2 Josephine Lontok, MD,1
Christopher Fecarotta, MD,3 Mengdan Liu,4 Jocelyn Sendecki,5 and Katherine Belden, MD1,6

Abstract

Eye disease is a well-documented complication of HIV infection. Opportunistic infections generally comprised
the majority of pre-antiretroviral therapy (ART) eye complications. With the introduction of ART, opportunistic
infections diminished. However, early ART regimens were cumbersome regarding side effects and pill burden,
making patient compliance difficult. Newer ART regimens are better tolerated and consist of fewer pills, theoretically making compliance easier and therapy more effective. The aim of this chart review study is to examine
eye disease epidemiology in HIV patients as ART has evolved. We reviewed 222 admissions at Thomas Jefferson
University Hospitals for 188 patients. These cases were divided into two groups. The first group was comprised
of patients admitted from 1995 through 2003, while the second group consisted of patients admitted from 2003 to
2010. Eye disease epidemiology was compared between the two groups. Our study did note a significant
decrease in eye diseases caused by opportunistic infections in the 2003–2010 patient group. Noninfectious eye
disease is a significant complication in this group.

increase in incidence of additional non-AIDS related comorbidities in today’s HIV patients (diabetes or hypertension, for instance).
The aim of this study is to review retrospectively a population of HIV-positive hospitalized patients with eye disease
over this time period of ART evolution. We then compare the
epidemiology of eye disease in patients seen in the early era of
ART with the more recent era of ART.

Introduction

I

n the pre-highly active antiretroviral therapy era
(HAART, or ART; please note that HAART serves as a
historical term for this article. We will refer to such HIV
treatment regimens as ‘‘antiretroviral therapy’’ or ART),
opportunistic infections of the eye were frequent and often
severe.1 However, the epidemiology of eye involvement in
HIV has changed as a result of our ability to control HIV
disease with newer ART regimens.2–7 The incidence and
overall severity of opportunistic infectious diseases of the
eye have decreased, along with other sequelae of immunosuppression.
The stark contrast in HIV eye diseases before and after
the introduction of ART has been described in the literature.8 However, epidemiologic differences in HIV eye disease that have occurred during the ART era have not been
as well established. Recent studies still estimate that approximately 40% of patients with AIDS and no evidence of
infectious retinitis still demonstrate significant visual impairment.9 Such ongoing disease may be indirectly due to a
persistent systemic inflammatory state (the hypothesized
etiology of HIV retinopathy) or due to the aforementioned

Methods
Patient population
HIV-infected adults with active ocular disease admitted as
inpatients for any reason to the Wills Eye Institute and Thomas Jefferson University Hospitals between December 30,
1995 and October 31, 2010 were identified through a search of
applied International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9) codes including HIV (042,
V08) and any ocular diagnosis (360–379).
An initial 422 admissions were identified. Of these, 9 charts
were unavailable, 129 admissions were noted to have no active ocular diagnosis, 59 were noted to be duplicate patient
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Table 1. Demographicsa

Demographics
Age (yrs) (median)
Gender (% male)
Race (%)
White non-hispanic
Black non-hispanic
Other
Substance abuse (%)
Tobacco abuse (%)
HIV history
Median time (yrs) since HIV diagnosis
Median CD4 + T-cells (cells/lL)
% CD4 + T-cells < 200 cells/lL
% Patients with HIV viral load > 400 copies/mL
Current antiretroviral therapy (%)
History of opportunistic infection
Selected co-morbidities (%)
Diabetes mellitus
Malignancy
Cardiovascular disease
Chronic kidney disease
Chronic viral hepatitis

All patients (n = 188) Early ART (n = 60) Late ART (n = 128)
50
68.6

51
73.3

50
66.4

26
68.6
5.4
32.8, n = 183
29, n = 183

15
81.7
3.3
31.6, n = 57
26.3, n = 57

31.2
62.4
6.4
33.3, n = 126
30.2, n = 126

6, n = 85
83, n = 143
72, n = 143
72.1, n = 86
58.5
47.4, n = 175
N = 183
13.7
11.5
20.8
8.2
20.8

6, n = 39
40, n = 50
88, n = 50
88.5, n = 26
51.7
72.2, n = 54
N = 57
7
1.8
15.8
8.8
17.5

7.5, n = 46
108, n = 93
63.4, n = 93
65, n = 60
61.7
36.4, n = 121
N = 126
16.7
15.9
23
7.9
22.2

p Value
0.2491
0.34
0.032

0.8149
0.5956
0.0673
< 0.0001
0.0052
0.0259
0.1922
< 0.0001
0.0784
0.0055
0.2644
1
0.47

a

Not all demographic information for each patient was available.

admissions without a new ocular diagnosis, and 3 admissions
did not have confirmed HIV by history or laboratory testing.
These cases were excluded, leaving 222 admissions amongst
188 patients.
A retrospective chart review was conducted. Data for the
study were collected from included charts. Demographic patient information collected included age, gender, race, substance abuse history, CD4 + T cells/lL, HIV viral load, current
antiretroviral therapy, and select co-morbidities (Table 1).
Outcome
Active ocular diagnoses were recorded for each admission.
Visual acuity was documented when available (160 of 188
patients had a full ophthalmologic exam with full visual
acuity). All patients in the study with documented visual
acuity received a full ophthalmologic exam. For the 22 patients
without documented visual acuity, documentation of further
ophthalmologic examination was not recorded.
Patients and their active ocular diagnoses were divided
into comparison groups based on date of presentation. An
‘‘Early ART’’ arm of the study consisted of presentations from
December 30, 1995 through June 30, 2003. A ‘‘Late ART’’ arm
of the study consisted of presentations from July 1, 2003
through October 31, 2010.
For this study, 2003 was chosen as a separation time point
between study groups. Prior to 2003, protease inhibitor (PI)
regimens still proved cumbersome and triple-nucleotide reverse transcriptase inhibitor (NRTI) regimens still remained in
use. In 2003 and beyond, newer, better-tolerated medications
such as atazanavir, fosamprenavir, and fixed-dose combination pills such as tenofovir/emtricitabine and tenofovir/
emtricitabine/efavirenz became available. Therefore, 2003
seemed a reasonable time to demarcate an ‘‘early’’ time frame
capturing patients on first-generation PIs and NRTIs versus a
‘‘late’’ time frame capturing patients on modern PIs, fixeddose combination pills, and NNRTIs.

Statistics
p Values were obtained with the unpaired t-test, chi-square
test, or Fisher’s exact test and adjusted by false discovery rate
methods, when indicated.
Results
From the 222 admissions, 252 active ocular diagnoses were
identified (please refer to Table 4 for a complete breakdown
by anatomic location). Sixty patients were included in the
early ART arm of the study, and 128 patients were included in
the late ART arm (Table 1).
Immunologic and virologic comparison of the two patient
groups illustrated a significantly higher median CD4 + count
in the late ART patients compared with the early ART patients
(108 vs. 40 cells/lL). The late ART group also had significantly fewer patients with uncontrolled viral load (defined
as > 400 copies/mL) compared with the early ART group
(65% vs. 88.5% of patients). In addition, late ART patients
were less likely to have had an opportunistic infection in the
past (36.4% of late ART patients had a history vs. 72.2% of
early ART patients).

Table 2. Infectious vs. Noninfectious
Ocular Diagnoses
Late
Early
Total
diagnoses (%) ART (%) ART (%)
N = 175 p Value
N = 77
N = 252
Infectious
diagnosis
Noninfectious
diagnosis

43

54.6

37.7

57

45.5

62.3

0.0129
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Table 3. Most Frequent Ocular Diagnoses By Early and Late ART Groups

Diagnosis

Total diagnoses (%)
N = 252

Early ART (%)
N = 77

Late ART (%)
N = 175

p Value

13.9
13.9
7.6
7.1
5.6
3.6
3.2
2.8
2.8
2.8
2.4
2.4
2.4
2.4
1.9
1.9

18.2
28.6
6.5
3.9
5.2
3.9
0
0
2.6
0
2.6
0
1.3
3.9
1.3
3.9

12
7.4
8
8.6
6.3
3.4
4.6
4
2.9
4
2.3
3.4
2.9
1.7
2.3
1.1

0.4097
< 0.0001
1
0.4097
1
1
0.4097
0.4097
1
0.4097
1
0.4097
1
0.7003
1
0.4097

Noninfectious retinopathy
CMV retinitis (Fig. 1)
Retinal detachment (Fig. 4)
Ulcerative keratitis
Necrotizing herpetic retinitis/viral retinitis (Fig. 2)
Preseptal cellulitis
Trauma
Cataract
Ocular syphilis
Cranial nerve palsy
Conjunctivitis
Conjunctival hemorrhage
Glaucoma
Noninfectious uveitis
Endogenous endophthalmitis
Optic neuritis

The late ART group of patients, however, tended to have
more co-morbidities compared to the early ART patients.
Most significantly, patients in the late ART group had a 15.9%
prevalence of malignancy versus only a 1.8% incidence in the
early ART group. Late ART patients also had a significantly
higher prevalence of diabetes mellitus compared to their early
ART counterparts (16.7% vs. 7% prevalence). While not statistically significant, late ART patients also tended to have a
higher prevalence of cardiovascular disease and chronic viral
hepatitis (Table 1).
Among the early ART patients, 77 ocular diseases were
diagnosed, while 175 ocular diseases were diagnosed in
the late ART group. Ocular disease in both groups combined
was predominately noninfectious (57%). Ocular diagnoses
were compared in early and late ART groupings. Early ART
diagnoses had significantly more infectious eye disease occurrence compared to the late ART group (54.6% of cases vs.
37.7%) (Table 2).
The most frequent ocular diagnoses (from Table 4) found in
the early and late ART groups were compared with p values
calculated for the differences in prevalence (Table 3) (note that
p values were not calculated for differences in all diagnoses
from Table 4, just for the most frequent that appear in Table 3).
Most notably, 28.6% of ocular disease in the early ART group
was CMV retinitis (Fig. 1) compared to only 7.4% in the late
ART group. This diagnosis represented the highest burden of
ocular disease in early ART patients by a large margin. In
contrast, the incidence of ocular disease diagnoses in the late
ART group was more evenly distributed amongst a wide
range of categories.
The late ART group did have a significantly higher rate of
severe vision impairment, however, when visual acuity was
documented. Forty-eight patients in the early ART group and
112 patients in the late ART group had visual acuity documented. While the percentage of patients with ‘‘mild’’ visual
impairment ( < 20/40 but ‡ 20/200) was roughly equal (22.9%
of early ART patients vs. 19.6% of late ART patients,
p value of 0.64), the percentage of patients with ‘‘severe’’ visual impairment ( < 20/200) was significantly more for the late
ART group (37.5% of early ART patients versus 58% of late
ART patients, p value of 0.02).

Discussion
Ocular disease is associated with human immunodeficiency virus (HIV) infection.10–12 Ocular manifestations
of HIV infection have been well described in the pre-ART era
of HIV infection when patients frequently developed severe immunodeficiency followed by the development of
opportunistic infections. Direct therapy (ganciclovir for cytomegalovirus, or CMV retinitis, for instance) for such opportunistic infections provided limited benefit in patients
suffering from a progressively failing immune system.13
With the approval of zidovudine as the first antiretroviral
therapy for HIV in 1987, the face of HIV disease began to
change. The most dramatic change came in the mid-1990s
with the introduction of ART, which made preservation of
T-cell immunity and suppression of HIV possible. Early ART
regimens, however, were inconvenient and cumbersome for
patients due to high pill burdens, food restrictions, and intolerable side effects.2–7 Drug compliance, and therefore
control of HIV disease, remained a challenge. With time,
however, drugs with better tolerability, potency, and efficacy
have been developed. Such developments have even made it
possible to include a complete ART regimen co-formulated
into one pill taken once daily. As a result, compliance and
control of HIV are now much more realistic goals.
Eye disease caused by infectious agents such as Toxoplasma
gondii (Fig. 5), varicella-zoster virus (VZV) (Fig. 3), and, most
notably, CMV (Fig. 1), were disproportionately represented in
HIV patients before HAART became widely available. One
autopsy study from the pre-ART era found a 32% incidence of
postmortem HIV-infected patients with evidence of CMV
retinitis,14 and that the incidence of clinically apparent CMV
retinitis in individuals with severe T-cell impairment (CD4 +
< 100 cells/lL) may be as high as 25%.15 Frequently, HIVinfected patients with CMV retinitis progressed to retinal
detachment and severe visual impairment months after the
onset of visual disturbance.
As control of HIV has improved, the incidence of opportunistic infections decreased.2–7,11 One epidemiologic study from
1996 to 2004 found a 92% decrease in AIDS-related mortality in
HIV patients while ART utilization increased from 43% to 82%
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Table 4. Active Ocular Diagnoses by Anatomic Location

Eye anatomic location
Adnexa/orbit
Eyelids
Preseptal cellulitis
Blepharitis (infectious)
Ectropion
Entropion
Orbit and surrounding tissues
Ocular invasive tumor
Orbital cellulitis
Thyroid ophthalmopathy/exophthalmos
Infected eye implant
Non-infectious frozen globe
Eyelid/orbit
Trauma
Lacrimal ducts
Dry eye syndrome
Dacryostenosis
Dacryostenosis (infectious)
Combined
Herpes zoster ophthalmicus
Anterior segment disease
Cornea
Ulcerative keratitis
Noninfectious
Infectious
Non-ulcerative keratitis
Corneal scar
Superficial punctate keratopathy
Lenses
Cataract
Presbyopia
Posterior synechiae
Lens dislocation
Conjunctiva
Acute conjunctivitis
Conjunctival hemorrhage
Anterior chamber
Glaucoma
Hyphema
Pupil
Pupillary margin degeneration
Anisocoria
Sclera
Episclertitis (infectious)
Posterior segment disease
Retina
CMV retinitis
Noninfectious retinopathy
HIV retinopathy (Fig. 2)
DM retinopathy
Retinal hemorrhage
HTN retinopathy
Sickle cell retinopathy
Retinal detachment
Retinal detachment
Proliferative vitreoretinopathy
Retinal tear
Necrotizing herpetic retinitis/viral retinitis
Cryptococcal retinitis
Lattice degeneration
Macular hole
Vitreous
Vitreous syneresis

All diagnoses (n = 252)

Early ART (n = 77)

Late ART (n = 175)

44 (17.4%)
15 (5.9%)
9 (3.6%)
3 (1.2%)
2 (0.8%)
1 (0.4%)
11 (4.4%)
4 (1.6%)
3 (1.2%)
2 (0.8%)
1 (0.4%)
1 (0.4%)
8 (3.2%)
8 (3.2%)
6 (2.4%)
4 (1.6%)
1 (0.4%)
1 (0.4%)
4 (1.6%)
4 (1.6%)
59 (23.4%)
24 (9.5%)
18 (7.1%)
7 (2.8%)
11 (4.4%)
3 (1.2%)
2 (0.8%)
1 (0.4%)
13 (5.2%)
7 (2.8%)
4 (1.6%)
1 (0.4%)
1 (0.4%)
12 (4.8%)
6 (2.4%)
6 (2.4%)
7 (2.8%)
6 (2.4%)
1 (0.4%)
2 (0.8%)
1 (0.4%)
1 (0.4%)
1 (0.4%)
1 (0.4%)
112 (44.4%)
107 (42.5%)
35 (13.9%)
35 (13.9%)
23 (9.1%)
9 (3.6%)
1 (0.4%)
1 (0.4%)
1 (0.4%)
19 (7.6%)
16 (6.3%)
2 (0.8%)
1 (0.4%)
15 (5.6%)
1 (0.4%)
1 (0.4%)
1 (0.4%)
1 (0.4%)
1 (0.4%)

10
5
3
2
0
0
1
0
1
0
0
0
0
0
4
4
0
0
0
0
11
5
3
2
1
2
0
0
2
0
2
0
0
2
2
0
1
1
0
0
0
0
1
1
45
45
22
14
11
2
0
1
0
5
4
0
1
4
0
0
0
0
0

34
10
6
1
2
1
10
4
2
2
1
1
8
8
2
0
1
1
4
4
48
19
15
5
10
1
2
1
11
7
2
1
1
10
4
6
6
5
1
2
1
1
0
0
67
62
13
21
12
7
1
0
1
14
12
2
0
11
1
1
1
1
1
(continued)
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Table 4. (Continued)

Eye anatomic location
Choroid
Choroidal hemorrhage
Choroidal detachment
Retina vessels
Retinal vein occlusion
Anterior/posterior segment disease
Ocular syphilis
Panuveitis
Retinitis
Noninfectious uveitis
Uveitis
Behcet’s uveitis
Iritis
Vitritis
Choroiditis
Endogenous endophthalmitis (bacterial)
Neuro-ophthalmic
Cranial nerves/extraocular muscles
Cranial nerve palsy
Noninfectious
Infectious
Optic nerve
Optic neuritis
Infectious
Noninfectious
Brain
Migraine with ocular pain
Hemianopsia
Encephalitis with photophobia (infectious)
Gaze preference (non-infectious)

FIG. 1. Cytomegalovirus retinitis. This
image was originally published in the
Retina Image Bank ASRS. Author, Jeremy
B. Gross, MD. Uploaded October 10, 2012.
Copyright 2013 American Society of Retina Specialists.

All diagnoses (n = 252)
2
1
1
2
2
18
7
5
2
6
1
1
1
2
1
5
19
7
7
6
1
5
5
4
1
7
3
2
1
1

(0.8%)
(0.4%)
(0.4%)
(0.8%)
(0.8%)
(7.1%)
(2.8%)
(1.9%)
(0.8%)
(2.4%)
(0.4%)
(0.4%)
(0.4%)
(0.8%)
(0.4%)
(1.9%)
(7.6%)
(2.8%)
(2.8%)
(2.4%)
(0.4%)
(1.9%)
(1.9%)
(1.6%)
(0.4%)
(2.8%)
(1.2%)
(0.8%)
(0.4%)
(0.4%)

Early ART (n = 77)

Late ART (n = 175)

0
0
0
0
0
6
2
2
0
3
0
0
1
1
1
1
5
0
0
0
0
3
3
2
1
2
0
1
1
0

2
1
1
2
2
12
5
3
2
3
1
1
0
1
0
4
14
7
7
6
1
2
2
2
0
5
3
1
0
1
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FIG. 2. HIV retinopathy. This
image was originally published
in the Retina Image Bank
ASRS. Author, Alex P. Hunyor,
MD. Uploaded January 11,
2013. Copyright 2013 American Society of Retina Specialists.

over this period16 (this includes eye diseases such as CMV: several epidemiologic studies of the late 1990’s estimate a 50–80%
decrease in the incidence of CMV retinitis alone since the introduction of ART17–19). Consequently, the incidence of non-AIDSrelated mortality significantly increased over this time period.2–7
Today’s HIV practitioners often face their most significant challenges from noninfectious co-morbidities such as coronary artery
disease, osteoporosis, chronic kidney disease, hyperlipidemia,
liver disease, and non-AIDS defining malignancies.
In our study, noninfectious eye disease was more common
overall than infectious disease. In the early ART group,
however, infections represented the majority of eye diseases
that were seen. The significant decrease in opportunistic in-

fections in the late ART group supports the conclusion that
ART may have been a less effective intervention in the early
ART group. The median time since HIV diagnosis in the early
and late groups was 6 and 7.5 years, respectively. Despite an
average year and a half added exposure to HIV infection, late
ART patients were far less likely to have had an opportunistic
infection. One could subsequently conclude that improved
efficacy of ART in the late group directly impacted the incidence of infectious eye diseases.
A bias towards an increased number of opportunistic infections in the early ART group may very well exist in this
study, however. Many patients in the early ART group may
have acquired their opportunistic infections prior to the

FIG. 3. Progressive outer retinal necrosis. This image was originally published in the Retina Image Bank ASRS.
Author, Mallika Goyal, MD. Uploaded
October 31, 2012. Copyright 2013
American Society of Retinal Specialists.
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FIG. 4. Acute retinal detachment. This image was originally published in the Retina Image Bank ASRS. Author, Jeffrey G. Gross, MD. Uploaded October 12, 2012. Copyright
2012 American Society of Retina Specialists.
availability of any effective antiretrovirals. They may have
subsequently survived long enough to be included in the
early ART group. Many such patients may not have survived
long enough, however, to be included in the late ART group.
A better understanding of HIV treatment and prevention of
opportunistic infections may have prevented acquisition of
such infections for late ART patients and may partially ac-

FIG. 5. Syphilitic maculopathy. This image was originally published in the Retina
Image Bank ASRS. Author,
Matthew W. MacCumber, MD,
PhD; co-author, Milad Hakimbashi, MD. Photographer,
Tara Farmer. Uploaded August 31, 2012. Copyright 2013
American Society of Retina
Specialists.
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count for the decreased prevalence of opportunistic infections
in the late ART group.
An additional caveat exists in that HIV eye diseases that
were frequently managed in the inpatient setting in the 1990s
can now be managed in the outpatient setting. For example, a
regimen of oral valganciclovir in combination with ART could
now potentially be used to treat CMV retinitis in the outpatient setting. However, such a diagnosis would almost universally prompt an inpatient admission in the time frame
captured by the early ART group. As this study only examined eye diseases in inpatients, fewer patients with true infectious eye disease may have been captured in the late ART
group, since these patients may have been able to avoid
hospital admission altogether.
In addition, lack of initial insurance reimbursement for PIs
made their availability to patients impractical in many cases
until the late 1990s. Therefore, despite the existence of PIs
throughout the early ART time period, these effective HIV
medications may not have been widely employed over that
same time frame, and opportunistic infections may therefore
have developed with greater frequency in this group.
The majority of patients with ocular disease, whether infectious or not, experienced diminished visual acuity (when
documented). Patients in the late ART group were significantly more likely to have documented visual acuity ( < 20/
200) as compared to early ART patients. Our data concur with
other larger studies10 that also illustrate that visual impairment remains a significant problem in the HIV population,
despite improved control of HIV. Emerging noninfectious eye
diseases in HIV patients are likely to continue to have an
impact on vision, despite improved control of HIV. HIV
practitioners, who may be unaware of the potential effects of
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for routine eye care as a component of the comprehensive
management of HIV infected patients.
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Alex P. Hunyor, MD. Uploaded January 11, 2013. Copyright
2013 American Society of Retina Specialists.

noninfectious causes of visual impairment, may inadvertently
leave evolving eye disease unaddressed.
In conclusion, ART has significantly changed the epidemiologic landscape of HIV disease. The incidence of lifethreatening opportunistic infections has significantly decreased
in the setting of newer, more efficacious, and better-tolerated
antiretroviral drugs for those individuals who are diagnosed,
who are retained in care, and who remain on ART with a
suppressed viral load. Noninfectious co-morbidities are often
of more pressing concern to the health of HIV patients taking
modern ART regimens.
This generalization appears to be true with regard to eye
disease in the HIV patient as well. Vision-threatening opportunistic infections such as CMV retinitis were commonly
seen prior to the development of antiretroviral medications.
Such infections still represented a significant disease burden
amongst patients taking early-generation ART regimens;
however, it appears that newer iterations of ART are causing a
decrease in the incidence of such opportunistic eye infections.
Noninfectious eye diseases now appear to be a more significant threat to vision in the late ART HIV patient.
These study data have several limitations. Most notably, this
study is a small, cross-sectional examination with an inherent
selection bias, since only hospitalized patients were included.
These data may not reflect a true representation of eye disease in
the general HIV population. Furthermore, patients without subjective eye complaints may have never received an ocular diagnosis, and therefore subclinical eye disease may not have been
discovered. Also of note, some demographic information for the
patients in this study was unavailable and therefore incomplete.
With these limitations in mind, we conclude that our data
provide evidence of a shift in the epidemiology of HIV eye
disease. Noninfectious pathology seems to be a more significant cause of visual loss in the late ART era. This observation
is consistent with the shifting epidemiology of HIV morbidity
and mortality in general and underscores the continued need
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